Document is current
Any future updates will be listed below
-
Authors
Tajima, Tsubasa
Kaga, Hideyoshi
Ito, Naoaki
Kogai, Toshiki
Naito, Hitoshi
Kakehi, Saori
Kadowaki, Satoshi
Nishida, Yuya
Kawamori, Ryuzo
Tamura, Yoshifumi
Watada, Hirotaka
-
Funding
Funding for this research was provided by:
Sumitomo Pharma, Co., Ltd.
- License Information
-
More Information
Article History
Received: 26 July 2024
Accepted: 10 September 2024
First Online: 30 September 2024
Declarations
:
: Ryuzo Kawamori has received lecture fees from Sumitomo Pharma Co. and Novo Nordisk Pharma. Yoshifumi Tamura has received research funds from Astellas Pharma Inc., Kowa Pharmaceutical Co. Ltd., and Curves Holdings Co. Ltd., and Lotte Co. Ltd., and lecture fees from Boehringer Ingelheim, Sumitomo Pharma Co., Eli Lilly, Kowa Pharmaceutical Co., Mitsubishi Tanabe Pharma Co., Novo Nordisk Pharma, Ono Pharmaceutical Co., and Lion Co. Hirotaka Watada has received lecture fees from Novo Nordisk Pharma Ltd., Nippon Boehringer Ingelheim Co., Sumitomo Pharma Co., Ltd., Eli Lilly Japan K.K, Roche DC Japan, MSD K.K., Sanwa Kagaku Kenkyusho Co., Ltd., Daiichi Sankyo Ltd., Kyowa Kirin Co., Ltd., Bayer Yakuhin, Ltd., Abbott Japan LLC, and Mitsubishi Tanabe Pharma Corporation; research funding from Sanwa Kagaku Kenkyusho Co., Ltd., Kowa Company, Ltd., Nippon Boehringer Ingelheim Co., Ltd., Sumitomo Pharma Co., Ltd., and SBI Pharma Co., Ltd. Tsubasa Tajima, Hideyoshi Kaga, Naoaki Ito, Toshiki Kogai, Hitoshi Naito, Saori Kakehi, Satoshi Kadowaki and Yuya Nishida declare that they have no conflicts of interest.
: The ethics committee of Juntendo University approved the study protocol (reference number J21-011). This study was registered in the Japan Registry of Clinical Trials (jRCTs031210600). This study is carried out in accordance with the principles outlined in the Declaration of Helsinki. Written informed consent was obtained from all the participants after a full explanation of the study.
